Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Naloxone Stories

2014-04-09 23:23:34

The auto-injector is designed to allow quick administration when drug overdose first occurs. LOS ANGELES, CA (PRWEB) April 09, 2014 Family members and caregivers of individuals with opiate drug addiction problems heaved a sigh of relief earlier this month when the FDA announced it was issuing fast-track approval to Evzio (naloxone hydrochloride), an injectable medication that can be administered to someone who is known or suspected to have had an overdose of opioid drugs. The drug will be...

2014-04-08 08:33:01

The auto-injector is designed to allow quick administration when drug overdose first occurs LOS ANGELES, April 8, 2014 /PRNewswire/ -- Family members and caregivers of individuals with opiate drug addiction problems heaved a sigh of relief earlier this month when the FDA announced it was issuing fast-track approval to Evzio (naloxone hydrochloride), an injectable medication that can be administered to someone who is known or suspected to have had an overdose of opioid drugs. The drug...

2014-04-07 12:32:56

First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., April 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL will be presented at the American Society of Addiction Medicine (ASAM) 45(th) Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida. Four abstracts will be presented highlighting data from the clinical development...

2014-04-07 08:30:13

RICHMOND, Va., April 7, 2014 /PRNewswire/ -- Kaleo (formerly Intelliject) today announced that it has entered into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaleo to support commercialization of EVZIO(TM)(naloxone hydrochloride injection) and development of key pipeline products. Under the financing, PDL provided $150 million in cash at closing and will receive interest on the principal outstanding. The note is backed by royalty payments on kaleo's first...

2014-04-03 12:29:15

First and only naloxone product specifically intended for emergency administration by family members or caregivers in settings where opioids may be present RICHMOND, Va., April 3, 2014 /PRNewswire/ -- Kaleo (formerly Intelliject) today announced that the U.S. Food and Drug Administration (FDA) has approved EVZIO(TM) (naloxone hydrochloride injection) for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO...

2014-04-02 12:07:35

Researchers offer immediate steps to address rise in deaths There are important parallels between the early years of the HIV/AIDS epidemic and the current epidemic of opioid addiction - ones that could trigger a significant shift in opioid addiction prevention, diagnosis and treatment. These are the findings of a comparative review of HIV/AIDS and addiction by researchers Josiah D. Rich, M.D., M.P.H., director of the Center for Prisoner Health and Human Rights, based at The Miriam...

2014-03-27 08:33:37

Ashfield Market Access to provide managed markets and trade support RALEIGH, N.C., March 27, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence. BUNAVAIL is currently under review at the U.S. Food and Drug...

2014-03-17 12:27:13

Developers Continue to Focus Efforts on Formulation Improvements, According to Findings from Decision Resources Group BURLINGTON, Mass., March 17, 2014 /PRNewswire/ -- Decision Resources Group finds that, according to insights from surveyed U.S. and European psychiatrists and U.S. managed care (MCO) pharmacy directors, a therapy resulting in reduced use of opioids compared with existing therapies is one of the greatest unmet needs in the treatment of opioid addiction. Although clinical data...

2014-03-11 16:26:19

PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Naloxone Hydrochloride Injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. Mylan's product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4 mg/mL, of Hospira Inc. Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including...

2014-03-05 08:28:31

RALEIGH, N.C., March 5, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 26(th) Annual ROTH Conference. The presentation is scheduled for Monday, March 10, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Ritz Carlton, Laguna Niguel in Dana Point, California. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO The New Drug Application...